百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688506 百利天恒

已收盘 11-22 15:00:01

{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":195.32,"timestamp":1732258801000,"preClose":200.91,"halted":0,"volume":1373107,"delay":0,"floatShares":90451000,"shares":401000000,"eps":9.4763,"marketStatus":"已收盘","marketStatusCode":5,"change":-5.59,"latestTime":"11-22 15:00:01","open":198,"high":200.9,"low":193.1,"amount":269000000,"amplitude":0.0388,"askPrice":195.32,"askSize":0,"bidPrice":195.09,"bidSize":2,"shortable":0,"etf":0,"ttmEps":9.4763,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":200.91,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":221,"lowLimit":180.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":401000000,"pbRate":18.46,"roa":"--","roe":"186.1%","epsLYR":-1.95,"committee":0.257143,"marketValue":78323000000,"floatMarketCap":17667000000,"peRate":20.61142,"changeRate":-0.0278,"turnoverRate":0.0152,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。","afterMarket":{"amount":0,"volume":0,"close":195.32,"buyVolume":0,"sellVolume":0,"time":1732260839464,"indexStatus":"已收盘 11-22 15:30:00","preClose":200.91}},"requestUrl":"/m/hq/s/688506/tweets","defaultTab":"tweets","newsList":[{"id":"2484740191","title":"百利天恒：11月20日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2484740191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484740191?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:33","pubTimestamp":1732102410,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月20日百利天恒发布公告称公司于2024年11月20日召开业绩说明会。具体内容如下：百利天恒2024年11月20日投资者关系活动主要内容。公告详情请查看附件百利天恒主营业务：药品的研发、生产与营销。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000033689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2484168123","title":"四川两家医药上市公司获上百家机构调研","url":"https://stock-news.laohu8.com/highlight/detail?id=2484168123","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484168123?lang=zh_cn&edition=full","pubTime":"2024-11-20 15:50","pubTimestamp":1732089025,"startTime":"0","endTime":"0","summary":"百利天恒成“最火”四川医药股具体来看，百利天恒是9月中旬以来调研机构数最多的川股。据统计，来自基金公司、证券公司、阳光私募、海外机构等各路机构，共有141家对百利天恒进行了调研。汇宇制药境外拓展受关注与此同时，汇宇制药也获得136家各路机构的调研，目前的调研机构家数仅次于百利天恒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120155124a247e70f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120155124a247e70f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506","159938"],"gpt_icon":0},{"id":"2484735180","title":"百利天恒-U涨5% 生物医药论坛召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2484735180","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484735180?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:01","pubTimestamp":1732068081,"startTime":"0","endTime":"0","summary":"消息解读近日，2024第二届浦江生物医药源头创新论坛在浦东召开。资金动向截止发稿，百利天恒-U获得主力净流出83万元，其中超大单流出561万元，大单流入478万元。主营业务及业绩百利天恒-U公司主营业务为药品的研发、生产及销售。最新财报显示，今年三季报，百利天恒-U实现营业收入56.63亿元，同比增长1399.22%，净利润为40.65亿元，同比增长889.23%，基本每股收益为10.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120100136abd0aced&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120100136abd0aced&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","BK0239","688506","161726"],"gpt_icon":0},{"id":"2483246048","title":"百利天恒：公司在2024ASH披露CD33ADC早期临床数据 BMS更新01D1全球临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2483246048","media":"海通证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483246048?lang=zh_cn&edition=full","pubTime":"2024-11-13 00:00","pubTimestamp":1731427200,"startTime":"0","endTime":"0","summary":"BMS 于近期发布2024 年三季度报告，其投资者演示文件中更新了对于BL-B01D1 2025 年的临床计划。一方面，BMS 预计2025 年读出01D1针对实体瘤的I 期爬坡临床试验的部分结果，并将其视为2025-2026 年关键的里程碑事件之一；另一方面，BMS 新计划于2025 年启动BL-B01D1 的注册性临床。我们认为上述两个事件或将是百利天恒2025 的重要催化剂。事件2：公司在2024 年美国血液学年会上公布CD33 ADC BL-M11D1I 期临床的部分爬坡数据，针对r/r AML 展现出良好的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411131246189f5966d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411131246189f5966d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2482011227","title":"三季度医药市场升温！迈瑞净利破百亿，振东、百利天恒、贝瑞基因等40家企业利润大爆发！","url":"https://stock-news.laohu8.com/highlight/detail?id=2482011227","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482011227?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:03","pubTimestamp":1731416623,"startTime":"0","endTime":"0","summary":"随着国内各大医药上市公司三季报的陆续披露，营收净利成为脍炙人口的话题，医药市场热度升温，引发投资者关注。第三季度实现营业收入3.22亿元，同比增长15.16%；归属于上市公司股东的净利润800.19万元，同比增长120.76%。医疗器械企业本次三季报中净利润增速同样有突出表现，中红医疗、康众医疗、贝瑞基因等值得我们关注。10月28日，贝瑞基因发布2024年三季报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112210746abba2099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112210746abba2099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239","BK0086","BK0028","BK0102","BK0081","BK0139","BK0042","159938","000710","BK0221"],"gpt_icon":0},{"id":"2482715895","title":"百利天恒-U大幅上涨 生物医药产业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2482715895","media":"智选洞察","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482715895?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:17","pubTimestamp":1731377821,"startTime":"0","endTime":"0","summary":"消息解读近年来，为了推动生物医药产业的快速发展，从中央到地方，都出台了一系列的支持政策。在这样的背景之下，虽然我国的生物医药产业起步较晚，但也借着这股东风，呈现出了蓬勃的发展态势。资金动向截止发稿，百利天恒-U获得主力净流出430万元，其中超大单流出372万元，大单流出56万元。主营业务及业绩百利天恒-U公司主营业务为药品的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112101749abb7b18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112101749abb7b18e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","688506","BK0239","161726"],"gpt_icon":0},{"id":"2482243767","title":"百利天恒-U大跌5.21% 获主力净流出308万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482243767","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482243767?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:38","pubTimestamp":1731289105,"startTime":"0","endTime":"0","summary":"11月11日，百利天恒-U股价大幅下跌，截至09点38分，百利天恒-U下跌5.21%，报187.46元/股，成交4563万元，换手率0.26%，振幅5.48%。资金动向截止发稿，百利天恒-U获得主力净流出308万元，其中超大单流入9万元，大单流出316万元。主营业务及业绩百利天恒-U公司主营业务为药品的研发、生产及销售。最新财报显示，今年三季报，百利天恒-U实现营业收入56.63亿元，同比增长1399.22%，净利润为40.65亿元，同比增长889.23%，基本每股收益为10.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111100551abb45456&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111100551abb45456&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2481072161","title":"百利天恒-U大幅上涨 获主力净流入62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481072161","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481072161?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:50","pubTimestamp":1731030624,"startTime":"0","endTime":"0","summary":"11月08日，百利天恒-U股价大幅上涨，截至09点50分，百利天恒-U上涨5.10%，报201.99元/股，突破200元整数关口，成交8669万元，换手率0.49%，振幅4.67%。资金动向截止发稿，百利天恒-U获得主力净流入62万元，其中超大单流出125万元，大单流入187万元。主营业务及业绩百利天恒-U公司主营业务为药品的研发、生产及销售。最新财报显示，今年三季报，百利天恒-U实现营业收入56.63亿元，同比增长1399.22%，净利润为40.65亿元，同比增长889.23%，基本每股收益为10.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108100531a2223a86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108100531a2223a86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2481927939","title":"百利天恒(688506.SH)：BL-M17D1(ADC)用于治疗晚期实体瘤患者的I期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2481927939","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481927939?lang=zh_cn&edition=full","pubTime":"2024-11-07 17:24","pubTimestamp":1730971469,"startTime":"0","endTime":"0","summary":"智通财金APP讯，百利天恒 发布公告，近日，公司的全资子公司SystImmune,Inc.收到美国食品药品监督管理局的通知，BL-M17D1用于治疗晚期实体瘤患者的I期临床试验申请已获得FDA许可。BL-M17D1是与BL-B16D1出自同一新的小分子技术平台、与BL-B16D1共享同一新的“连接子+毒素”平台的ADC药物，其适应症为晚期实体瘤。包括本次BL-M17D1新获得FDA许可，截至目前，公司共有6个项目已获FDA许可开展临床研究，其他5个分别是：BL-B01D1、BL-M07D1、SI-B001、BL-M05D1、BL-M11D1在美国的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4023","ADC","03347","BK1141","688506","BL","LU0757428866.USD","LU1815336091.USD","BK4231","BK4080","BK0239","BK1576"],"gpt_icon":0},{"id":"2480135892","title":"创新药企三季报：君实、信达、荣昌、百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2480135892","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480135892?lang=zh_cn&edition=full","pubTime":"2024-11-02 10:49","pubTimestamp":1730515776,"startTime":"0","endTime":"0","summary":"另外，截至目前信达生物还有5个品种在国家药监局审评中，3个新药分子进入3期或关键性临床研究，另外约17个新药品种已进入临床研究。研发方面，2024年前三季度，百利天恒的累计研发投入约为9.32亿元，同比也大幅增加了80.34%，但占营收的比重则减少了120.33个百分点，为16.45%。百利天恒方面表示，研发投入的增加，主要是因为临床试验费持续增加。截至2024年9月30日，百利天恒的经营活动现金流净额约为44.94亿元，期末现金及现金等价物约为49.23亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102105112ab967177&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102105112ab967177&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688506"],"gpt_icon":0},{"id":"2480003186","title":"百利天恒：创新管线快速推进 国际化积极布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2480003186","media":"华西证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480003186?lang=zh_cn&edition=full","pubTime":"2024-11-01 00:00","pubTimestamp":1730390400,"startTime":"0","endTime":"0","summary":"公司创新药方面，BL-B01D1 单药正在进行 7 个 III 期注册临床试验，包括 2 个非小细胞肺癌适应症、1 个小细胞肺癌适应症、2 个乳腺癌适应症、 1 个食管鳞癌适应症、 1 个鼻咽癌适应症。风险提示新药研发不及预期，市场竞争加剧，产品上市后商业化表现不及预期，集采中标及降价影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411011831229f58fe9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411011831229f58fe9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2479579117","title":"【机构调研记录】银河基金调研伟星股份、百利天恒等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479579117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479579117?lang=zh_cn&edition=full","pubTime":"2024-10-31 08:04","pubTimestamp":1730333092,"startTime":"0","endTime":"0","summary":"；公司盐酸二甲双胍片通过仿制药一致性评价5）华阳集团 个股亮点：公司共同投资设立珠海横琴中科华创投资合伙企业；公司子公司华阳多媒体为星闪联盟会员单位；公司已获得小鹏汇天飞行汽车液晶仪表定点项目。旗下最近一年表现最佳的公募基金产品为银河沪深300价值指数A，最新单位净值为1.84，近一年增长21.59%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100011346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0253","BK0239","688506","002003"],"gpt_icon":0},{"id":"2479269433","title":"百利天恒（688506）2024年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2479269433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479269433?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:17","pubTimestamp":1730240274,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百利天恒发布2024年三季报。根据财报显示，百利天恒营收净利润同比双双增长。截至本报告期末，公司营业总收入56.63亿元，同比上升1399.22%，归母净利润40.65亿元，同比上升889.23%。归属于上市公司股东的净利润466,634.00万元，较上年同期增加499,465.91万元。2024年3月，公司已收到由BMS支付的8亿美元不可撤销不可抵扣首付款。此外，2024年上半年，公司创新药和传统业务板块合计获得13项临床批件，19项注册批件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000005921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506"],"gpt_icon":0},{"id":"2479342064","title":"百利天恒(688506)9月30日股东户数0.41万户，较上期减少20.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479342064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479342064?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:10","pubTimestamp":1730193017,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百利天恒披露，截至2024年9月30日公司股东户数为4098.0户，较6月30日减少1065.0户，减幅为20.63%。在化学制药行业个股中，百利天恒股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.11万户。从股价来看，2024年6月30日至2024年9月30日，百利天恒区间涨幅为7.89%，在此期间股东户数减少1065.0户，减幅为20.63%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900030632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2478488609","title":"百利天恒(688506.SH)发布前三季度业绩，净利润40.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478488609","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478488609?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:57","pubTimestamp":1730120273,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)发布2024年第三季度报告，公司前三季度营业收入56...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/16.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/16.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688506"],"gpt_icon":0},{"id":"2478104556","title":"百利天恒前三季度净利40.65亿元，同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104556","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478104556?lang=zh_cn&edition=full","pubTime":"2024-10-28 19:55","pubTimestamp":1730116500,"startTime":"0","endTime":"0","summary":"微成都报道10月28日晚间，百利天恒发布三季度业绩公告称，2024年前三季度营收约56.63亿元，同比扭亏为盈；归属于上市公司股东的净利润约40.65亿元；基本每股收益10.14元。其中，第三季度亏损超6亿元，公告解释亏损的原因主要是报告期内研发投入增加所致。百利天恒前三季度营收大幅增长的原因，主要是上半年收到海外客户首付款。微成都记者就相关问题联系百利天恒方面，截至发稿，对方未予回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028195558ab7b8b09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028195558ab7b8b09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2478800935","title":"广发基金吴兴武旗下广发保健A三季报最新持仓，重仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2478800935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478800935?lang=zh_cn&edition=full","pubTime":"2024-10-25 21:53","pubTimestamp":1729864386,"startTime":"0","endTime":"0","summary":"证券之星消息，10月25日广发基金旗下吴兴武管理的广发医疗保健股票型基金公布三季报，近1年净值增长率-2.02%。与上一季度相比，该基金前十大重仓股新增新产业，山东药玻，昆药集团，康龙化成；其中百利天恒持仓占比6.15%，为该基金第一大重仓股；诺泰生物，片仔癀，同仁堂，健民集团等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500046085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2477884319","title":"百利天恒-U10月21日主力资金流出845万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2477884319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477884319?lang=zh_cn&edition=full","pubTime":"2024-10-21 15:19","pubTimestamp":1729495157,"startTime":"0","endTime":"0","summary":"10月21日, 百利天恒-U股价涨1.53%，报收197.42元，成交金额4.10亿元，换手率2.29%，振幅5.95%，量比1.41。百利天恒-U今日主力资金净流出845万元，连续7日净流出，上一交易日主力净流出795万元，今日环比增加6.29%。近一年数据显示，该股主力连续7日净流出后，次日下跌概率为40.00%，平均跌幅为2.39%。该股近5个交易日下跌1.78%，主力资金累计净流出5593万元，其中3个交易日为股价上涨时净流出；近20日主力资金累计净流出637万元，其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410211536309f5324e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410211536309f5324e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2476285224","title":"百利天恒-U大幅上涨5.18% 郑州金水产业投资基金备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2476285224","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476285224?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:18","pubTimestamp":1729228682,"startTime":"0","endTime":"0","summary":"10月18日，百利天恒-U股价大幅上涨，截至13点18分，百利天恒-U上涨5.18%，报198.00元/股，成交1.74亿元，换手率1.00%，振幅6.23%。消息解读10月17日，郑州金水产业投资基金合伙企业在中基协备案。该基金规模50.01亿元，其中郑州金水投资集团认缴出资50亿元，深圳华信柏年股权投资基金管理有限公司认缴出资100万元。主营业务及业绩百利天恒-U公司主营业务为药品的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018134514ab6b0b0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018134514ab6b0b0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2476124414","title":"百利天恒：公司获得密集催化 中美临床持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2476124414","media":"海通证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476124414?lang=zh_cn&edition=full","pubTime":"2024-10-18 00:00","pubTimestamp":1729180800,"startTime":"0","endTime":"0","summary":"事件1：公司核心管线EGFR*HER3 双抗ADC BL-B01D1 在中美的临床持续获得进展，我们认为其后续临床开发及上市流程有望加，且我们看好01D1向前线拓展的潜力。事件2：公司在研管线CD33 ADC BL-M11D1 获FDA 批准启动I 期临床，建议关注公司其他在研管线的潜在机会。10 月14 日，公司旗下CD33 ADCBL-M11D1）用于治疗复发或难治性急性髓系白血病患者的 I 期临床试验申请获得 FDA 批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101811261995b1035f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101811261995b1035f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","stockEarnings":[{"period":"1week","weight":0.0701},{"period":"1month","weight":-0.0013},{"period":"3month","weight":0.0852},{"period":"6month","weight":0.0874},{"period":"1year","weight":0.7136},{"period":"ytd","weight":0.3961}],"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","perCapita":"22071股","boardName":"医药制造业","registeredCapital":"40100万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　四川百利天恒药业股份有限公司主营业务为药品的研发、生产及销售。公司主要产品包括：好好黄芪（黄芪颗粒）、新博柴黄（柴黄颗粒）、杜拉宝（消旋卡多曲颗粒）、新博林（利巴韦林颗粒）、奥博林（奥硝唑胶囊）、乐维静（丙泊酚注射液）、派斯欣（注射用甲磺酸帕珠沙星）等。公司获得了“四川省企业技术中心”、“高新技术企业”等。公司经过长期的行业和市场积累，逐步建立起良好的口碑和市场影响力，组建了完善的销售团队和销售体系，营销网络遍布全国30多个省、200余个地级市，实现了对不同地域的覆盖，以及“高—中—低”多层级市场的全面渗透。","serverTime":1732319290473,"listedPrice":24.7,"stockholders":"4098人(较上一季度减少20.63%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}